Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors

2025-523067-38-01 · tracked via the Priya Life Science EU tracker

Sponsor

Bristol-Myers Squibb Services Unlimited Company

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

21/07/2026

Enrollment target

Sites

Spain, France, Italy

Condition studied

Advanced Malignant Tumors; High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC)

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523067-38-01 on CTIS ↗ ← All trials in the EU